8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Mar 31, 2026·SEC
Co-Diagnostics, Inc.(CODX)Earnings, Financials & Key Ratios
CODX•NASDAQ
Price updated Jun 19, 2026
AboutCo-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Show more
- Revenue$622K-84.1%
- EBITDA-$30M+22.0%
- Net Income-$47M-24.6%
- EPS (Diluted)-35.25+5.2%
- Gross Margin64.28%-13.7%
- EBITDA Margin-4847.72%-390.4%
- Operating Margin-5025.53%-390.9%
- Net Margin-7533.62%-683.6%
- ROE-125.16%-133.3%
CODX Key Insights
Co-Diagnostics, Inc. (CODX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 99 (top 1%)
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 61.6% over 5 years
- ✗Shares diluted 31.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CODX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CODX Price & Volume
Co-Diagnostics, Inc. (CODX) stock price & volume — 10-year historical chart
Loading chart...
CODX Growth Metrics
Co-Diagnostics, Inc. (CODX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years51.15%
5 Years-61.6%
3 Years-73.7%
TTM-79.47%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-35.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM5.59%
Return on Capital
10 Years-234.3%
5 Years-30.67%
3 Years-58.68%
Last Year-80.33%
CODX Recent Earnings
Co-Diagnostics, Inc. (CODX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 3/12 qtrs (25%)
Q4 2025Latest
Nov 13, 2025Metric
Actual
Est
EPS
$4.80+15.9%
$5.71
Rev
$145,380+15.4%
$126,000
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.23+8.0%
$0.25
Rev
$162,910-45.7%
$300,000
Q2 2025
May 8, 2025Metric
Actual
Est
EPS
$0.24+27.3%
$0.33
Rev
$50,277-73.2%
$187,500
Q2 2025
Mar 27, 2025Metric
Actual
Est
EPS
$0.36-5.9%
$0.34
Rev
$149,325-60.2%
$375,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 13, 2025 | $4.80vs $5.71+15.9% | $145,380vs $126,000+15.4% |
| Q3 2025 | Aug 14, 2025 | $0.23vs $0.25+8.0% | $162,910vs $300,000-45.7% |
| Q2 2025 | May 8, 2025 | $0.24vs $0.33+27.3% | $50,277vs $187,500-73.2% |
| Q2 2025 | Mar 27, 2025 | $0.36vs $0.34-5.9% | $149,325vs $375,000-60.2% |
Based on last 12 quarters of dataView full earnings history →
CODX Peer Comparison
Co-Diagnostics, Inc. (CODX) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 QDEL | 930.68M | 13.67 | -0.82 | -1.89% | -45.57% | -56.31% | 1.46 | |
 FLGT | 535.45M | 18.00 | -9.14 | 13.83% | -18.75% | -5.42% | 0.00 | |
 CLOV | 2.59B | 5.00 | -29.41 | 40.34% | -2.58% | -17.08% | ||
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 IDXX | 44.64B | 562.09 | 42.97 | 10.42% | 24.63% | 70.87% | 0.67 | |
 NEOG | 2.03B | 9.31 | -1.85 | -3.2% | -68.47% | -28.64% | 0.44 | |
 CHEK | 10.88M | 1.86 | -0.43 | -226.19% |
Compare CODX vs Peers
Co-Diagnostics, Inc. (CODX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CODX Income Statement
Co-Diagnostics, Inc. (CODX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.66K | 39.91K | 214.97K | 74.55M | 97.89M | 34.22M | 6.81M | 3.92M | 622.49K | 718.17K |
Revenue Growth % | - | 420.9% | 438.63% | 34579.9% | 31.3% | -65.04% | -80.09% | -42.53% | -84.1% | -79.47% |
Cost of Goods Sold | 302 | 9.39K | 112.43K | 16.59M | 11.57M | 5.48M | 4.18M | 999.12K | 222.38K | 650K |
COGS % of Revenue | 3.94% | 23.53% | 52.3% | 22.25% | 11.82% | 16.02% | 61.43% | 25.52% | 35.72% | - |
Gross Profit | 7.36K▲ 0% | 30.52K▲ 314.7% | 102.54K▲ 236.0% | 57.96M▲ 56424.0% | 86.31M▲ 48.9% | 28.74M▼ 66.7% | 2.63M▼ 90.9% | 2.92M▲ 11.0% | 400.11K▼ 86.3% | 68.17K▲ 0% |
Gross Margin % | 96.06% | 76.47% | 47.7% | 77.75% | 88.17% | 83.98% | 38.57% | 74.48% | 64.28% | 9.49% |
Gross Profit Growth % | 119.63% | 314.67% | 235.99% | 56424.01% | 48.91% | -66.7% | -90.86% | 11% | -86.28% | - |
Operating Expenses | 4.57M | 6.15M | 6M | 16.27M | 40.25M | 55.72M | 45.33M | 43M | 31.68M | 32.01M |
OpEx % of Revenue | 59663.63% | 15405.12% | 2789.31% | 21.82% | 41.12% | 162.83% | 665.49% | 1098.23% | 5089.8% | - |
Selling, General & Admin | 3.52M | 4.74M | 4.56M | 12.94M | 24.95M | 21.61M | 21.14M | 20.64M | 11.44M | 10.98M |
SG&A % of Revenue | 45973.66% | 11867.45% | 2120.7% | 17.36% | 25.49% | 63.15% | 310.34% | 527.19% | 1837.69% | - |
Research & Development | 1M | 1.36M | 1.37M | 3.19M | 14.96M | 17.44M | 22.96M | 20.98M | 19.14M | 20.2M |
R&D % of Revenue | 13092.76% | 3410.47% | 637.95% | 4.27% | 15.29% | 50.96% | 337.09% | 535.86% | 3074.31% | - |
Other Operating Expenses | 45.76K | 50.77K | 65.9K | 138.63K | 335.36K | 16.67M | 1.23M | 1.38M | 1.11M | 826.36K |
Operating Income | -4.56M▲ 0% | -6.12M▼ 34.0% | -5.89M▲ 3.7% | 41.69M▲ 807.4% | 46.06M▲ 10.5% | -26.98M▼ 158.6% | -42.71M▼ 58.3% | -40.08M▲ 6.1% | -31.28M▲ 22.0% | -31.94M▲ 0% |
Operating Margin % | -59567.57% | -15328.65% | -2741.61% | 55.93% | 47.06% | -78.85% | -626.92% | -1023.75% | -5025.53% | -4447.41% |
Operating Income Growth % | -170.39% | -34.04% | 3.66% | 807.42% | 10.48% | -158.57% | -58.29% | 6.15% | 21.95% | - |
EBITDA | -4.52M | -6.07M | -5.83M | 41.83M | 46.4M | -25.7M | -41.48M | -38.7M | -30.18M | -30.86M |
EBITDA Margin % | -58966.42% | -15201.45% | -2710.95% | 56.11% | 47.4% | -75.1% | -608.86% | -988.57% | -4847.72% | -4296.78% |
EBITDA Growth % | -173.74% | -34.29% | 3.94% | 817.8% | 10.92% | -155.38% | -61.4% | 6.68% | 22.03% | 16.71% |
D&A (Non-Cash Add-back) | 46.06K | 50.77K | 65.9K | 138.63K | 335.36K | 1.28M | 1.23M | 1.38M | 1.11M | 1.08M |
EBIT | -6.65M | -6.14M | -6.09M | 41.69M | 46.06M | -11.59M | -42.71M | -40.08M | -31.28M | -31.94M |
Net Interest Income | -306.4K | -115.14K | -69.78K | 97.22K | 45.63K | 704.04K | 1.16M | 1.09M | 292.93K | -6.63K |
Interest Income | 3.83K | 19.8K | 36.65K | 97.22K | 45.63K | 704.04K | 1.16M | 1.09M | 292.93K | -6.63K |
Interest Expense | 310.23K | 134.95K | 106.44K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -2.4M | -153.91K | -301.82K | 875.42K | -429.16K | 8.13M | 4.6M | 2.5M | -17.23M | -18.19M |
Pretax Income | -6.96M▲ 0% | -6.27M▲ 9.9% | -6.2M▲ 1.2% | 42.57M▲ 787.1% | 45.64M▲ 7.2% | -18.85M▼ 141.3% | -38.11M▼ 102.2% | -37.58M▲ 1.4% | -48.51M▼ 29.1% | -50.13M▲ 0% |
Pretax Margin % | -90827.88% | -15714.27% | -2882% | 57.1% | 46.62% | -55.08% | -559.46% | -959.9% | -7793.22% | -6980.3% |
Income Tax | 0 | -18.96K | 0 | 90.54K | 8.98M | -4.61M | -2.78M | 57.37K | -1.62M | -1.63M |
Effective Tax Rate % | 0% | 0.3% | 0% | 0.21% | 19.67% | 24.45% | 7.29% | -0.15% | 3.33% | 3.25% |
Net Income | -6.96M▲ 0% | -6.27M▲ 9.9% | -6.2M▲ 1.2% | 42.48M▲ 785.6% | 36.66M▼ 13.7% | -14.24M▼ 138.8% | -35.33M▼ 148.2% | -37.64M▼ 6.5% | -46.9M▼ 24.6% | -48.5M▲ 0% |
Net Margin % | -90827.88% | -15714.27% | -2882% | 56.98% | 37.45% | -41.61% | -518.68% | -961.37% | -7533.62% | -6753.69% |
Net Income Growth % | -260.83% | 9.88% | 1.21% | 785.63% | -13.7% | -138.84% | -148.15% | -6.53% | -24.59% | -35.25% |
Net Income (Continuing) | -6.96M | -6.27M | -6.2M | 42.48M | 36.66M | -14.24M | -35.33M | -37.64M | -46.9M | -48.5M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -18.90▲ 0% | -15.00▲ 20.6% | -11.09▲ 26.1% | 1.52▲ 113.7% | 36.90▲ 2327.6% | -13.57▼ 136.8% | -36.00▼ 165.3% | -37.20▼ 3.3% | -35.25▲ 5.2% | -21.52▲ 0% |
EPS Growth % | -270.59% | 20.63% | 26.07% | 113.71% | 2327.63% | -136.78% | -165.29% | -3.33% | 5.24% | 5.59% |
EPS (Basic) | -18.90 | -15.00 | -11.09 | 1.59 | 38.10 | -13.57 | -36.00 | -37.20 | -35.25 | - |
Diluted Shares Outstanding | 365.34K | 416.15K | 558.56K | 933.35K | 996.79K | 1.05M | 978.22K | 1.01M | 1.33M | 2.25M |
Basic Shares Outstanding | 365.34K | 416.15K | 558.56K | 890.67K | 962.49K | 1.05M | 978.22K | 1.01M | 1.33M | 2.25M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CODX Balance Sheet
Co-Diagnostics, Inc. (CODX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 4.45M | 1.05M | 1.58M | 68.36M | 115.12M | 92.73M | 62.14M | 32.29M | 13.69M | 9.78M |
Cash & Short-Term Investments | 3.53M | 950.24K | 893.14K | 47.31M | 89.86M | 81.26M | 58.55M | 29.75M | 11.88M | 8.23M |
Cash Only | 3.53M | 950.24K | 893.14K | 42.98M | 88.61M | 22.97M | 14.92M | 2.94M | 11.88M | 8.23M |
Short-Term Investments | 0 | 0 | 0 | 4.34M | 1.26M | 58.29M | 43.63M | 26.81M | 0 | 0 |
Accounts Receivable | 0 | 13.42K | 131.38K | 12.14M | 20.91M | 5.4M | 330.88K | 132.57K | 190.38K | 82.39K |
Days Sales Outstanding | - | 122.73 | 223.07 | 59.42 | 77.99 | 57.59 | 17.73 | 12.36 | 111.63 | 185.87 |
Inventory | 9.07K | 18.15K | 197.17K | 8M | 2M | 5.31M | 1.66M | 1.07M | 992.4K | 846.12K |
Days Inventory Outstanding | 10.96K | 705.55 | 640.09 | 175.89 | 63.2 | 353.64 | 145.19 | 391.89 | 1.63K | 563.38 |
Other Current Assets | 0 | 0 | 0 | 547.22K | 0 | 0 | 1.6M | 0 | 626.09K | 622.76K |
Total Non-Current Assets | 210.45K | 501.26K | 631.07K | 2.88M | 44.91M | 30.35M | 33.18M | 31.71M | 11.05M | 11.72M |
Property, Plant & Equipment | 165.57K | 156.14K | 196.83K | 949.64K | 1.93M | 2.91M | 6M | 4.88M | 3.48M | 4.16M |
Fixed Asset Turnover | 0.05x | 0.26x | 1.09x | 78.51x | 50.63x | 11.75x | 1.13x | 0.80x | 0.18x | 0.18x |
Goodwill | 0 | 0 | 0 | 0 | 14.71M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 27.2M | 26.77M | 26.4M | 26.1M | 7.22M | 7.22M |
Long-Term Investments | 44.88K | 345.12K | 434.24K | 1.93M | 1M | 672.68K | 773.38K | 731.07K | 350.57K | 2.06M |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 75K | 0 | 0 | 0 | 0 | 0 |
Total Assets | 4.66M▲ 0% | 1.55M▼ 66.7% | 2.22M▲ 42.6% | 71.24M▲ 3115.7% | 160.03M▲ 124.6% | 123.09M▼ 23.1% | 95.32M▼ 22.6% | 64M▼ 32.9% | 24.74M▼ 61.3% | 21.5M▲ 0% |
Asset Turnover | 0.00x | 0.03x | 0.10x | 1.05x | 0.61x | 0.28x | 0.07x | 0.06x | 0.03x | 0.02x |
Asset Growth % | 259.8% | -66.69% | 42.63% | 3115.65% | 124.65% | -23.09% | -22.56% | -32.86% | -61.34% | -202.97% |
Total Current Liabilities | 628.26K | 2.35M | 328.07K | 4.06M | 12.6M | 3.87M | 5.75M | 7.32M | 3.54M | 4.28M |
Accounts Payable | 40.82K | 148.97K | 5.96K | 598.32K | 607.51K | 952.3K | 1.48M | 3.29M | 1.88M | 2.02M |
Days Payables Outstanding | 49.33K | 5.79K | 19.35 | 13.16 | 19.16 | 63.42 | 129.27 | 1.2K | 3.08K | 981.24 |
Short-Term Debt | 0 | 1.91M | 0 | 0 | 0 | 0 | 0 | 0 | 662.26K | 857.64K |
Deferred Revenue (Current) | 10.79K | 0 | 1.32K | 305.31K | 150K | 0 | 362.45K | 0 | 14.8K | 61.26K |
Other Current Liabilities | 0 | 0 | 0 | 0 | 5.77M | 1.69M | 1.42M | 543.68K | 984.34K | 1.41M |
Current Ratio | 7.09x | 0.45x | 4.83x | 16.83x | 9.14x | 23.94x | 10.81x | 4.41x | 3.87x | 2.28x |
Quick Ratio | 7.07x | 0.44x | 4.23x | 14.86x | 8.98x | 22.57x | 10.52x | 4.27x | 3.59x | 2.09x |
Cash Conversion Cycle | - | -4.96K | 843.82 | 222.15 | 122.03 | 347.81 | 33.66 | -799.21 | -1.34K | -232 |
Total Non-Current Liabilities | 183.55K | 260K | 150K | 477.83K | 12.96M | 4.69M | 3.56M | 2.37M | 574.3K | 1.17M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 574.3K | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 50.71K | 2.15M | 1.24M | 0 | 3.35M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 7.23M | 2.42M | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 260K | 150K | 477.83K | 5.73M | 2.22M | 1.41M | 1.14M | 0 | 0 |
Total Liabilities | 811.8K | 2.61M | 478.07K | 4.54M | 25.56M | 8.57M | 9.31M | 9.69M | 4.11M | 5.46M |
Total Debt | 0 | 1.91M | 0 | 0 | 0 | 347.92K | 2.99M | 2.15M | 1.24M | 2.03M |
Net Debt | -3.53M | 958.34K | -893.14K | -42.98M | -88.61M | -22.63M | -11.93M | -784.37K | -10.65M | -6.2M |
Debt / Equity | - | - | - | - | - | 0.00x | 0.03x | 0.04x | 0.06x | 0.13x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.07x |
Net Debt / EBITDA | - | - | - | -1.03x | -1.91x | - | - | - | - | 0.20x |
Interest Coverage | -21.43x | -45.48x | -57.21x | - | - | - | - | - | - | - |
Total Equity | 3.85M▲ 0% | -1.06M▼ 127.5% | 1.74M▲ 264.1% | 66.7M▲ 3739.2% | 134.48M▲ 101.6% | 114.52M▼ 14.8% | 86.01M▼ 24.9% | 54.31M▼ 36.9% | 20.63M▼ 62.0% | 16.04M▲ 0% |
Equity Growth % | 228.58% | -127.5% | 264.08% | 3739.19% | 101.62% | -14.84% | -24.89% | -36.86% | -62.02% | -209.28% |
Book Value per Share | 10.54 | -2.54 | 3.11 | 71.46 | 134.91 | 109.14 | 87.93 | 53.71 | 15.51 | 7.12 |
Total Shareholders' Equity | 3.85M | -1.06M | 1.74M | 66.7M | 134.48M | 114.52M | 86.01M | 54.31M | 20.63M | 16.04M |
Common Stock | 12.32K | 12.92K | 17.34K | 28.56K | 33.82K | 34.75K | 36.11K | 37.9K | 67.7K | 69.21K |
Retained Earnings | -12.42M | -18.69M | -24.97M | 17.51M | 54.17M | 39.93M | 4.6M | -33.04M | -80.37M | -89.51M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -14.21M | -15.58M | -15.58M | -15.58M | -15.58M |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 293.14K | 146.7K | 418.44K | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CODX Cash Flow Statement
Co-Diagnostics, Inc. (CODX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.21M | -4.08M | -5.53M | 28.17M | 41.08M | 6.57M | -22.08M | -29.16M | -29.14M | -28.24M |
Operating CF Margin % | -41913.35% | -10222.84% | -2570.12% | 37.78% | 41.97% | 19.2% | -324.16% | -744.67% | -4680.71% | - |
Operating CF Growth % | -144.72% | -27.05% | -35.42% | 609.77% | 45.86% | -84.01% | -436.17% | -32.03% | 0.06% | -5.96% |
Net Income | -6.96M | -6.27M | -6.2M | 42.48M | 36.66M | -14.24M | -35.33M | -37.64M | -46.9M | -48.5M |
Depreciation & Amortization | 45.76K | 50.77K | 65.9K | 138.63K | 335.36K | 1.28M | 1.23M | 1.38M | 1.11M | 1.08M |
Stock-Based Compensation | 2.03M | 1.33M | 1.09M | 2.74M | 5.51M | 7.54M | 8.34M | 5.43M | 2.25M | 1.59M |
Deferred Taxes | 0 | 0 | 243.03K | -547.22K | 930.08K | -4.81M | -2.42M | 0 | 0 | 0 |
Other Non-Cash Items | 2.17M | 38.76K | 91.43K | 176.59K | 544.46K | 10.6M | 460.32K | -1.08M | 17.57M | 18.53M |
Working Capital Changes | -504.75K | 769.77K | -818.28K | -16.82M | -2.9M | 6.19M | 5.64M | 2.75M | -3.17M | -943.22K |
Change in Receivables | -698.39K | -13.42K | -121.46K | -12.96M | -8.74M | 14.92M | 2.54M | 186.39K | -31.8K | 80.04K |
Change in Inventory | -9.07K | -9.09K | -179.01K | -7.92M | 5.71M | -3.67M | 413.14K | 265.49K | 131.27K | 278.7K |
Change in Payables | 8.37K | 85.95K | -226.66K | 3.76M | -299.94K | -2.48M | 1.77M | 2.16M | -3.11M | -919.87K |
Cash from Investing | -189.31K | -380.34K | -435.25K | -5.82M | 4.1M | -58.17M | 15.39M | 17.07M | 26.27M | 18.77M |
Capital Expenditures | -129.31K | -41.34K | -113.25K | -774.4K | -669.46K | -1.43M | -1.37M | -748.35K | -700.05K | -750.15K |
CapEx % of Revenue | 1687.63% | 103.57% | 52.68% | 1.04% | 0.68% | 4.17% | 20.04% | 19.11% | 112.46% | 104.45% |
Acquisitions | 0 | 0 | -322K | -714.5K | 1.69M | 0 | 0 | -143.75K | -102.57K | -102.57K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -322K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 5.94M | 1.88M | 5.9M | 19.74M | 450.4K | -14.03M | -1.36M | 103.91K | 11.81M | 15.79M |
Debt Issued (Net) | -41.5K | 2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 7.07M | 30K | 6.5M | 19.47M | 450.4K | -14.21M | -1.36M | 103.91K | 11.81M | 15.78M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -14.21M | -1.36M | 0 | 0 | 0 |
Other Financing | -1.09M | -153.84K | -592.76K | 272.68K | 0 | 177.87K | 0 | 0 | 0 | 12.5K |
Net Change in Cash | 2.54M▲ 0% | -2.58M▼ 201.9% | -57.1K▲ 97.8% | 42.08M▲ 73802.8% | 45.63M▲ 8.4% | -65.63M▼ 243.8% | -8.06M▲ 87.7% | -11.98M▼ 48.7% | 8.95M▲ 174.7% | 6.33M▲ 0% |
Free Cash Flow | -3.34M▲ 0% | -4.12M▼ 23.4% | -5.64M▼ 36.8% | 27.39M▲ 585.8% | 40.41M▲ 47.5% | 5.14M▼ 87.3% | -23.45M▼ 556.1% | -29.9M▼ 27.5% | -29.84M▲ 0.2% | -28.99M▲ 0% |
FCF Margin % | -43600.98% | -10326.41% | -2622.8% | 36.74% | 41.28% | 15.02% | -344.2% | -763.78% | -4793.17% | -4036.41% |
FCF Growth % | -152.22% | -23.37% | -36.81% | 585.8% | 47.54% | -87.28% | -556.06% | -27.54% | 0.22% | 2.88% |
FCF per Share | -9.14 | -9.90 | -10.09 | 29.35 | 40.54 | 4.90 | -23.97 | -29.57 | -22.43 | -12.86 |
FCF Conversion (FCF/Net Income) | 0.46x | 0.65x | 0.89x | 0.66x | 1.12x | -0.46x | 0.62x | 0.77x | 0.62x | 0.60x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 5.4M | 4.5M | 55.98K | 0 | 858.87K | 858.87K |
CODX Key Ratios
Co-Diagnostics, Inc. (CODX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -1626.11% | -449.31% | -1826.4% | 124.14% | 36.45% | -11.44% | -35.24% | -53.65% | -125.16% | -164.92% |
Return on Invested Capital (ROIC) | - | -4256.48% | -1188.83% | 254.6% | 99.3% | -29.38% | -38.59% | -47.11% | -73.89% | -117.71% |
Gross Margin | 96.06% | 76.47% | 47.7% | 77.75% | 88.17% | 83.98% | 38.57% | 74.48% | 64.28% | 9.49% |
Net Margin | -90827.88% | -15714.27% | -2882% | 56.98% | 37.45% | -41.61% | -518.68% | -961.37% | -7533.62% | -6753.69% |
Debt / Equity | - | - | - | - | - | 0.00x | 0.03x | 0.04x | 0.06x | 0.13x |
Interest Coverage | -21.43x | -45.48x | -57.21x | - | - | - | - | - | - | - |
FCF Conversion | 0.46x | 0.65x | 0.89x | 0.66x | 1.12x | -0.46x | 0.62x | 0.77x | 0.62x | 0.60x |
Revenue Growth | - | 420.9% | 438.63% | 34579.9% | 31.3% | -65.04% | -80.09% | -42.53% | -84.1% | -79.47% |
Related:CODX Dividend History·CODX Revenue History·CODX Price History·CODX P/E History·CODX Financial Ratios·CODX Institutional Holders
CODX SEC Filings & Documents
Co-Diagnostics, Inc. (CODX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CODX Frequently Asked Questions
Co-Diagnostics, Inc. (CODX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Co-Diagnostics, Inc. (CODX) reported $0.7M in revenue for fiscal year 2025.
Co-Diagnostics, Inc. (CODX) saw revenue decline by 84.1% over the past year.
Co-Diagnostics, Inc. (CODX) reported a net loss of $48.5M for fiscal year 2025.
Dividend & Returns
Co-Diagnostics, Inc. (CODX) has a return on equity (ROE) of -125.2%. Negative ROE indicates the company is unprofitable.
Co-Diagnostics, Inc. (CODX) had negative free cash flow of $29.0M in fiscal year 2025, likely due to heavy capital investments.